Skip to main content

Table 3 Breast tumor protein expression and the first site of distant recurrence

From: Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study

    

First distant site of breast cancer recurrence

 

Protein

No. of breast cancers with protein expression/No. of breast cancers examined

No. of first metastatic sites from cancers with protein expression/No. of all first metastatic sitesa

Bone

Liver

Lung

Skin

Brain

Other

 

n/Nb (%)

n/N (%)

n/Nc (%)

n/Nc (%)

n/Nc (%)

n/Nc (%)

n/Nc (%)

n/Nc (%)

COX2

108/232 (46.6)

150/319 (47.0)

47/108 (43.5)***

24/108 (22.2)

32/108 (29.6)*

11/108 (10.2)

7/108 (6.5)

29/108 (26.9)

HER2

66/234 (28.7)

91/321 (28.3)

29/66 (43.9)**

18/66 (27.3)

18/66 (27.3)**

9/66 (13.)

1/66 (1.5)

16/66 (24.2)

ER

142/232 (61.2)

192/317 (60.6)

85/142 (59.9)**

31/142 (21.8)

20/142 (14.1)*

17/142 (12.0)

3/142 (2.1)**

36/142 (25.4)

PgR

106/230 (46.1)

143/316 (45.3)

62/106 (58.5)

24/106 (22.6)

13/106 (12.3)**

11/106 (10.4)

1/106 (0.9)**

32/106 (30.2)

EGFR

36/196 (18.4)

64/269 (23.8)

16/36 (44.4)

11/36 (30.6)

15/36 (41.7)****

6/36 (16.7)

3/36 (8.3)

13/36 (36.1)

CK5

21/207 (10.1)

30/285 (10.5)

9/21 (42.9)

3/21 (14.3)

7/21 (33.3)**

1/21 (4.8)

4/21 (19.0)**

6/21 (28.6)

Nestin

19/206 (9.2)

27/284 (9.5)

10/19 (52.6)

3/19 (15.8)

4/19 (21.1)

2/19 (10.5)

3/19 (15.8)*

5/19 (26.3)

Prominin-1

15/180 (8.3)

23/246 (9.3)

6/15 (40.0)

3/15 (20.0)

4/15 (26.7)

1/15 (6.7)

3/15 (20.0)**

6/15 (40.0)

SMA

9/219 (4.1)

13/300 (4.3)

4/9 (44.4)

2/9 (22.2)

2/9 (22.2)

0/9 (0.0)

2/9 (22.2)*

3/9 (33.3)

SNAI1

145/214 (67.8)

200/296 (67.6)

87/145 (60.0)**

28/145 (19.3)***

22/145 (15.2)

17/145 (11.7)

5/145 (3.4)

41/145 (28.3)

SNAI2

59/222 (26.6)

81/304 (26.6)

33/59 (55.9)

13/59 (22.0)

13/59 (22.0)

3/59 (5.1)*

3/59 (5.1)

16/59 (27.1)

CK18

215/222 (96.8)

294/303 (97.0)

114/215 (53.0)

53/215 (24.7)

39/215 (18.1)

22/215 (10.2)

10/215 (4.7)

56/215 (26.0)

E-cadherin

189/211 (89.6)

259/288 (89.9)

104/189 (55.0)

46/189 (24.3)

34/189 (18.0)

16/189 (8.7)*

8/189 (4.2)

51/189 (27.0)

KIT

17/210 (8.1)

26/291 (8.9)

9/17 (52.9)

4/17 (23.5)

2/17 (11.8)

3/17 (17.6)

2/17 (11.8)

6/17 (35.3)

GATA3

151/219 (68.9)

209/302 (69.2)

88/151 (58.3)

38/151(25.2)

21/151 (13.9)*

16/151 (10.6)

5/151 (3.3)

41/151 (27.2)

Ki67

112/220 (50.9)

154/299 (51.5)

59/112 (52.7)

30/112(26.8)

24/112 (21.4)

9/112 (8.0)

5/112 (4.7)

27/112 (24.1)

p53

57/213 (26.8)

86/292 (29.5)

30/57 (52.6)

18/57 (31.6)

15/57 (26.3)*

5/57 (8.8)

3/57 (5.3)

15/57 (26.3)

  1. aOne breast cancer may have given rise to more than one first metastatic sites.
  2. bTwo to 54 tumors were not analyzed due to lack of tissue material.
  3. cThe number of first metastatic sites from cancers with the protein expression/the number of breast cancers that expressed the protein.
  4. *P < 0.10, **P < 0.05, ***P < 0.01, ****P < 0.001.
  5. CK5, cytokeratin-5; CK18, cytokeratin 18; COX2, cyclooxygenase 2; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GATA3, GATA binding protein 3; HER2, human epidermal growth factor receptor-2; PgR, progesterone receptor; SMA, smooth muscle actin.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us